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Skeletal muscle injuries are common in athletes, occurring with direct and indirect mechanisms and marked residual eﬀects, such
as severe long-term pain and physical disability. Current therapy consists of conservative management including RICE protocol
(rest,ice,compressionandelevation),nonsteroidalanti-inﬂammatorydrugs,andintramuscularcorticosteroids.However,current
management of muscle injuries often does not provide optimal restoration to preinjury status. New biological therapies, such as
injection of platelet-rich plasma and stem-cell-based therapy, are appealing. Although some studies support PRP application in
muscle-injury management, reasons for concern persist, and further research is required for a standardized and safe use of PRP
in clinical practice. The role of stem cells needs to be conﬁrmed, as studies are still limited and inconsistent. Further research is
needed to identify mechanisms involved in muscle regeneration and in survival, proliferation, and diﬀe r e n t i a t i o no fs t e mc e l l s .
1.Introduction
Skeletal muscle injuries are common causes of severe long-
term pain and physical disability, accounting for up to 55%
of all sports injuries [1]. Contusions and strains are the
most frequent muscle lesions, representing more than 90%
of all sports-related injuries [2]. Mechanisms of muscle le-
sion can be divided into direct and indirect trauma. Direct
injuries include lacerations and contusions, while indirect
injuries include complete or incomplete muscle strains [3].
A muscle contusion takes place when a sudden, heavy com-
pressive force is applied to the muscle [4]. A muscle strain
occurs when an excessive tensile force is applied to the
muscle leading to the overstraining of the myoﬁbers up to a
rupture near the myotendinous junction [5]. Muscle injuries
can also result from a combination of these mechanisms.
Finally, skeletal muscle can be damaged when compartment
syndromes occur because of vascular and/or neurologic
impairment [3, 6]. Injuries can counter the beneﬁcial eﬀects
of sports participation because of the residual eﬀects [7–19].
Theassociatedmorbidity,includingpainfulcontracturesand
muscle atrophy, can result in prolonged loss of activity and
increased risk of recurrent injury [20]. In some instances,
muscle injuries leads to inability of athletes to continue to
practice sport [7].
Therefore, there is a need to improve skeletal muscle
injury management. Conservative management is com-
monly accepted, according to the principle that “muscle
injuries do heal conservatively”. It follows the RICE protocol
(rest, ice, compression, and elevation). Other therapies
include the local application of heat and passive motion
exercises. Drug therapy typically consists of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and intramuscular cor-
ticosteroids.
Operative management is required only in selected pa-
tients, such as athletes with a large intramuscular hematoma,
a complete strain of a muscle with no agonist muscles, a par-
tial strain when more than 50% of the muscle belly is dam-
aged, or persisting extension pain (>6 months) in a previ-
ously injured muscle [21].2 Stem Cells International
As current therapy does not seem to obtain complete res-
toration of preinjury status, new biological therapies could
represent interesting and more eﬀective strategies to manage
muscle injuries [22, 23]. Biological therapies include cell
therapy,tissueengineering,andtheadministrationofgrowth
factors [24–26] with the goal of enhancing current therapies.
This paper provides an overview on current biological
strategies for the management of patients with muscle inju-
ries. The rationale behind these therapies and the best avail-
able evidence therapeutic options are reported.
2. GrowthFactors
The healing process of the injured skeletal muscle is charac-
terized by several bioactive molecules, including proinﬂam-
matory cytokines, transforming growth factor-beta (TGF-
β) superfamily members, and angiogenic factors. For this
reason, the growth factors and the cytokines represent a
potential therapeutic option to improve the regeneration/re-
pair process of injured skeletal muscles. These signaling
molecules accelerate the regeneration of injured muscular
tissue, providing a mitogenic stimulus activating myogenic
precursor cells [27].
Each of these molecules shows speciﬁc biological activ-
ities. The transforming growth factor-beta (TGF-β)s t i m u -
lates mesenchymal cell proliferation [28], promotes the pro-
liferation of ﬁbroblasts [29] and the biosynthesis of extra-
cellular matrix, particularly type I collagen [30], regulates
endothelial cell activity and angiogenesis [31], and inhibits
satellite cell proliferation and diﬀerentiation [27]. Fibroblast
growth factor (FGF) promotes proliferation of ﬁbroblasts
[32], stimulates satellite cells proliferation but inhibits their
diﬀerentiation [33], and promotes the mitogenesis of mes-
enchymal cells [27]. Epidermal growth factor (EGF) stim-
ulates ﬁbroblasts migration and proliferation and regulates
angiogenesis and extracellular matrix homeostasis [34]. The
platelet-derived growth factor (PDGF) promotes the mito-
genesis of mesenchymal cells and ﬁbroblasts [35], induces
proliferation of satellite cells, and inhibits the end stages of
myoblast diﬀerentiation [36]. Vascular endothelial growth
factor (VEGF) promotes endothelial cells mitogenesis and
migration [37] and stimulates myoblast migration [38]. The
neoangiogenesis plays a critical role in the healing process
of muscle injuries. The new vessels sprout from the health
tissue surrounding the lesion and provide the supply of
oxygen, growth factor, and blood stem cell to enhance the
regeneration process [39]. Thus, the restoration of vascular
pattern in the injured area represents an early and necessary
phase for regeneration and morphological and functional
recovery of muscle tissue.
Based on the multitude of their biological eﬀects, the
clinical application of growth factors is aﬀected by con-
siderable side eﬀects. An overexpression of growth factors
such as TGF-β and FGF has been related to inhibition
of myoblasts diﬀerentiation and muscle-ﬁber regeneration
[33].Inaddition, growthfactorsexplain theirstimulatory ef-
fect on both muscle cells and ﬁbroblasts. Particularly, TGF-β
is one of the most important growth factors related to scar
formation during healing, and it seems to drive the diﬀer-
entiationofmyogeniccellsintomyoﬁbroblasticcells.Forthis
reason,muscle-ﬁberregenerationandscar-tissueproduction
can be considered two concomitant and competitive pro-
cesses [40–57].
Also, the expression of growth factors is closely regulated
by a large number of extracellular matrix (ECM) proteins,
namely, the heparin sulfate proteoglycans and the small
leucine-rich proteoglycans (SLRPs) [58, 59]. Several growth
factors need to bind the heparan sulphate proteoglycans
and the SLRPs to provide their biological eﬀects. Thus, the
application of growth factors to promote healing of the
damaged muscle tissue should include the administration of
these speciﬁc ECM molecules [13, 14, 16, 60–76].
To date, available data from experimental settings are
contradictory. Some authors did not report any beneﬁcial
eﬀectsbytheadministrationofFGF-2[77] or overexpression
of skeletal muscle speciﬁc isoform of IGF-1 (mIGF-1) at the
injured region [78]. FGF-2, IGF-1, and nerve growth factors
can promote muscle healing process, increasing resistance
to tensile loading when compared to untreated muscles [79,
80]. Moreover, mouse myoblasts transduced with the IGF-I
gene increase their growth rate and enhance the contractile
force production of skeletal muscle substitutes consisting of
hydrogel and IGF-I engineered myoblasts [81].
A combination of growth factors can be used to regulate
the diﬀerent process of regeneration of muscle tissue and
scar-tissue production. Thus, the application of IGF-I com-
bined withTGF-β allows to induce muscle regeneration, pre-
venting the formation of a ﬁbrous scar [82].
3.Platelet-RichPlasma(PRP)
Platelet-rich plasma (PRP) therapy represents an interesting
biological technique to provide tissue repair by inducing
chemotactic, proliferative, and anabolic host cellular re-
sponses[83].PRPisanautologousproductconsistingofbio-
active agents derived from patients’ own platelets [84–86].
Usually, PRP is administered by local injection of the PRP
solution or the application of a PRP gel at the time of surgery
[87].
Given the large amount of biological agents required for
tissue repair, PRP could be an ideal biological autologous
product providing a balanced combination of mediators able
to improve the healing process. In clinical practice, the blood
clot at the site of injury is replaced with a smaller volume of
PRP solution or gel. The increased concentration of platelet
atthesiteoflesionprovidesahigherconcentrationofhealing
bioactive factors than in physiological conditions. To date,
PRP has been proposed for management of tendon [88–90],
ligament [91, 92], muscle [93], nerve [94, 95], bone [96, 97],
and joint injuries [98, 99].
Theeﬀectivenessofautologousconditionedserum(ACS)
has been compared with Traumeel/Actovegin in a non-
randomized nonblinded pilot study (level III) on muscle
strain injuries in professional sportsmen [93]. The ACS was
obtained from whole blood, and it contained bioactive pro-
teins including interleukin-1β (IL-1β), TNF-α,I L - 7 ,ﬁ b r o -
blast growth factor-2 (FGF-2), IL-1Ra, HGF, PDGF-AB,
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containing both botanical and mineral ingredients in home-
opathic concentrations. Actovegin is a deproteinized calf
blood hemodialysate consisting of a physiological mix of
amino acids. Although both treatments were safe, the ACS
allowed to reduce the time to full recovery and the amount
of edema and/or bleeding at MRI images.
These ﬁndings have been also conﬁrmed in professional
soccer players with muscle lesions varying for size and loca-
tion [100]. Athletes were managed with activated pure PRP
(P-PRP) injections. Full resumption of normal training ac-
tivities was restored in half of the expected time compared
to matched historical controls. The same leukocyte-free PRP
preparation has been found eﬀective to manage adductor
longus strain in a professional bodybuilder [101].
ACS and PRP have been also evaluated in laboratory
settings. ACS was compared with saline solution in a contu-
sion injury model. ACS showed an earlier activation and/or
recruitment of satellite cells, and an earlier fusion, with larg-
er regenerating myoﬁbers, compared with controls [102].
PRP increases proliferation of muscle cells, diﬀerentiation of
satellite cells and synthesis of angiogenic factors in an in vitro
setting [103]. PRP and leukocyte and platelet-rich plasma
(L-PRP) have been also compared in a laboratory-con-
trolled study using a muscle strain rat model. The authors
demonstratedthatPRPismoreeﬀectivethanL-PRPinterms
of myogenesis enhancement and contractile function [104].
Although preliminary data are encouraging, there are
some reasons of concern about PRP treatment. First of all,
PRP could induce a ﬁbrotic healing response in muscle tis-
sues, by increasing local concentration of TGF. According to
experimental data, TGF seems to be able to induce ﬁbrosis
in cultured muscle tissue [27]. Moreover, the eﬀectiveness of
PRP could be aﬀected by leukocytes within the injected solu-
tion, because their enzymes (proteases and acid hydrolases)
can damage muscle tissue [105].
Finally, several devices and systems are available for
PRP preparation. Therefore, PRP products applied in several
studies consist of a basic mixture of grow factors including
diﬀerent concentration of each single agent. Moreover, level
I studies performed with adequate outcome measures and
follow-up assessment are lacking.
To date, no PRP formulation has solid evidence of ef-
fectiveness to heal muscle injuries. Pilot clinical studies indi-
cate that PRP therapies may enhance muscle repair after
strain or contusion. Moreover, laboratory data indicate the
ability of several growth factors to enhance myogenesis.
However, at present, there is no evidence to recommend or
discourage the adoption of PRP in clinical practice [25, 26,
106–129]. Further research is required to standardize formu-
lations (number of platelets and/or leukocytes) and admin-
istration regimens, including volume of injection and timing
of treatment, to optimize PRP application for management
of muscle injuries.
4. Cell Therapy
Inthelastdecade,regenerativemedicineandtissueengineer-
ing increased their role in management of musculoskeletal
diseases. Transplantation of stem cells has been considered
a new strategy to repair injured tissues [130–142]. Diﬀerent
areas of application have been explored, such as articular
cartilage [143–146], bone [147–150], ligament, and tendon
[151–155]. The expectations for future therapeutic strategies
are great.
The idea of cell therapies for muscle regeneration has
beendevelopedfromtheobservationthatskeletalmusclehas
regenerative capacity [156–158] .S e v e r a ls t u d i e sh a v ei n v e s -
tigated the role of stem cells in muscle healing, showing their
direct participation in tissue regeneration and their inﬂu-
ence in healing modulation [30, 159, 160]. However, severe
muscle injuries are characterized by concomitant activation
of regenerative activities of the satellite cells and proﬁbrotic
activities of ﬁbroblasts [161, 162].
The speciﬁc expression pattern of growth factors in the
region of injury determines the dominant cell type in the
wound healing process [30]. High levels of TGF-β3a r e
related to the activation of mesenchymal progenitor cells
(MPCs)derivedfromtraumatizedmuscletopromotewound
healing after muscle injury [163]. On the other hand, high
levels of TGF-β1 are related to activation of ﬁbroblasts to
produce disorganized extracellular matrix leading to ﬁbrosis
in the muscle tissue [159, 160]. The ﬁbrotic tissue aﬀects the
ability of the satellite cells to repair the muscle tissue.
There are distinct subsets of myogenic cells. Muscle sat-
ellite cells (SCs) are localized under the basal lamina of mus-
cle-ﬁbers [164].Theyrespond toregenerativestimulibypro-
liferating to form myoblasts which, in turn, diﬀerentiate and
fuse in multinucleated myotubes [165, 166]. Their capability
to renew and to produce diﬀerentiated progeny suggests
that they are the adult stem-cell population of skeletal mus-
cle [167]. They are also known as Pax7+ cells, based on their
expression of the muscle-speciﬁc paired box (Pax) trans-
cription factor Pax7 [168]. However, SCs consist of hetero-
geneous cell population, including Myf5+ cells (90%) and
Myf5-cells (10%) [169]. The ﬁrst of them are committed to
the myogenic lineage because of expression of Myf5 which is
an initiator of myogenic diﬀerentiation [170].
Otherstemcellshavebeenidentiﬁed.Theyarebothmus-
cle speciﬁc, such as mesoangioblasts and pericytes, skeletal
muscle precursors (SMPs), muscle stem cells (MuSCs), side-
population (SP) cells, and PW1-cells, and nonspeciﬁc, such
as embryonic stem (ES) cell, amniotic ﬂuid stem (AFS) cells,
mesenchymal stem cells (MSCs), and mesenchymal cells
frombonemarrow[171].Theyareabletocontributetomus-
cle regeneration with diﬀerent myogenic potential, but their
potential is still undeﬁned. Satellite cells seem to be suﬃcient
for the regenerative need of damaged adult skeletal muscle
in vivo [172]. The MSCs present a great migration potential
toward the areas of induced muscle degeneration and un-
dergo myogenic diﬀerentiation, providing regeneration of
muscle tissue. The MSC transduction with transcription fac-
tors, such as MyoD, has been also investigated to enhance
their potential of myogenic diﬀerentiation [173].
The properties of the stem cells in the muscle have been
analyzed using animal models of muscle dysfunctions and
injuries. Improved muscular structure has been observed in
mice used as Duchene Muscular Dystrophy models treated
with stem cells [174–176]. Better muscle regeneration has4 Stem Cells International
been obtained by the use of muscle-derived stem cells
(MDSCs) in models of induced skeletal muscle injury [177].
MDSCs provide an improvement of muscle healing because
of their ability to recruit capillaries and nerves into the in-
jured region [177]. They are also able to diﬀerentiate directly
into endothelial cells and cell types with neuronal character-
istics [178]. For these reasons, muscle regeneration seems to
be more powerful with MDSCs application compared with
satellite cells application.
A model of hindlimb ischemia, analogous to exercise-in-
duced compartment syndrome, showed potential beneﬁt of
injections of marrow-derived stromal cells in term of per-
fusion, ﬁbrosis development, and atrophy [179]. Results
from ongoing studies on MDSCs implantation after muscu-
loskeletal contusion are awaited [162].
The role of stem cells in musculoskeletal disease needs to
be conﬁrmed. Studies are still limited, and many questions
are still unanswered. Several issues should be taken into ac-
count, such as safety and eﬃcacy, immunogenicity, and bio-
chemical factors involved in survival and diﬀerentiation of
stemcells. Furtherresearchis needed to identify mechanisms
involved in muscle regeneration to exactly understand the
therapeutic potential of stem cells.
5. Scaffolds
Regenerative medicine is a multidisciplinary approach to
produce living, functional substitutes for restoration, main-
tenanceorimprovementofthefunctionofdamagedtissueor
organ. Tissue engineering is a speciﬁc approach included in
regenerative medicine ﬁeld. The tissue engineering consists
ofassociationofthreemainelements:cells,factorsorstimuli,
and biomaterials [180].
Musculoskeletal tissue engineering aims to obtain func-
tional replacement of lost or damaged bone, cartilage, skel-
etal muscle, and tendon/ligament [8, 15, 17–19, 22, 181–
195]. In skeletal muscle injuries, tissue engineering repre-
sents a biological alternative for replacement of large tissue
loss after severe damage.
Skeletalmuscletissueengineering couldbeperformedby
twodiﬀerentapproaches:invitroandinvivo.Ininvitrotissue
engineering, SCs from adult skeletal muscle are expanded
and seeded on a 3D scaﬀold to produce a cell-biomaterial
construct. After the diﬀerentiation of stem cells, the neo-
tissue graft could be transplanted in the injured region. In
in vivo tissue engineering, the isolated SCs are charged on
a3 Ds c a ﬀold carrier and promptly transplanted. Thus, the
delivery of stem cells in the muscle lesion is obtained [171].
Eﬃcient skeletal muscle regeneration is strongly related
with features of biomaterials used to fabricate scaﬀold and
with the regenerative potential of cells used for scaﬀold seed-
ing. The source of cells used for scaﬀold seeding should be
chosen based on the features of the damaged tissue. Cells can
be autologous or allogeneic, including also stem cells where
it is required.
The scaﬀold is a 3D-structure able to mimic the anatom-
ical and biomechanical properties of the native tissue. The
scaﬀold for muscle tissue engineering should be able to ﬂex
and stretch [196]. Moreover, they should be able to promote
the alignment of myoblasts the assembly of myotubes. Nano-
structuredscaﬀoldsaremoreeﬃcientinpromotingmyotube
assembly than microstructured scaﬀolds [197].
The biomaterials used to fabricate scaﬀold can be natural
(like collagen)or synthetic (e.g.,ceramics,polymers of lactic,
and glycolic acid) and soluble or insoluble. Scaﬀold must
have biocompatibility and biodegradability properties [198].
Biocompatibility is essential to prevent toxicity and immu-
nogenicity biomaterial-related inducing the immune-re-
sponse in the host muscle. Biodegradability allows gradual
substitution of the scaﬀo l db yt h en e w l yf o r m e dm u s c l et i s -
sue. Moreover, the scaﬀold should integrate molecules or
cells,providingacontrolleddeliveryofgrowthfactors,cytok-
ines,plasmids,drugs,orotheranabolicstimuli[199–202].In
skeletal muscle tissue engineering, biomaterials should sup-
port the myogenic process, providing a microenvironment
which allows cell survival, proliferation and/or diﬀerenti-
ation to repair, and/or regenerate the damaged tissue [9–
11, 23, 203–221].
Both synthetic and natural scaﬀolds have been investi-
gated for tissue engineering approaches to muscle regenera-
tion.Thepolylactic-co-glycolicacid(PGA)isasyntheticbio-
degradable biomaterial showing appropriate rigidity and
connection, appropriate for muscle tissue engineering. Con-
structs of myoblasts and polyglycolic acid meshes have been
evaluated in a muscle regeneration rat model. Regenerate
tissue-likestructureshavebeenfoundwithalignedmyoblasts
along strands of polymer ﬁbers. The PGA scaﬀold allowed
the alignment of myoblasts and the assembly of myotubes,
reproducing the organization of muscle ﬁbres [222].
In the ﬁeld of natural biodegradable biomaterials, dif-
ferent 3D scaﬀolds have been developed. Collagen scaﬀolds
with parallel oriented pores have been used to reproduce
the three-dimensional organization of skeletal muscle [223].
Permanent myogenic cells were inﬁltrated in these scaﬀolds
and were cultured to induce their proliferation and diﬀer-
entiation [223]. The collagen scaﬀold with oriented pore
structure showed the ability to induce skeletal muscle-like
tissue regeneration with aligned multinucleated myotubes
according to the orientation of pore structure [223]. In addi-
tion,cell-scaﬀoldconstructswereabletosupportmechanical
forces generated in muscle tissue [223]. These results have
been also found in an in vitro study in which a multilayered
cultures of rat neonatal satellite cells in collagen 3D scaﬀolds
were performed [224].
Fibrin is another natural biodegradable 3D scaﬀold used
toobtainmuscleregeneration.Three-dimensionalﬁbrinma-
trixhasbeenusedascarriertoinjectmyoblastsintheinjured
muscle region of a rat model. The ﬁbrin carrier induced no
inﬂammatory reaction and allowed integration of myoblasts
into host muscle-ﬁbers [225]. The ﬁbrin matrix also allows
to produce strained ﬁbrin gel by applying continuous tensile
strain to ﬁbrin scaﬀold. The morphological features of
strainedﬁbringelsinducethealignmentofseededmyoblasts.
Moreover, the aligned cells are parallel to the direction of
the strain reproducing the organization of skeletal muscle
tissue [226]. The ﬁbrin matrix also allows the diﬀerentiation
of myoblasts, cultured in a three-dimensional pattern, under
electrical stimulation [227]. Finally, ﬁbrin scaﬀolds haveStem Cells International 5
been also combined with adult human cells to regenerate
muscle after large tissue loss in a mouse model with large
defect of tibialis anterior muscle. Constructs of ﬁbrin micro-
threads and adult human cells were used, showing the role
of constructs in host tissue regeneration by forming skeletal
muscle-ﬁbers, connective tissue, and PAX7 positive cells
[228].
Another type of natural scaﬀold is a hyaluronan-based
hydrogel that has been used to perform the delivery of either
SCs or MPCs in a mice model. The construct SC-hydrogel
showed more enhancement of regeneration process with a
higher number of new myoﬁbers than MPC-hydrogel or hy-
drogel alone. In the muscle receiving the SCs, there was a
functional SC niche associated with neural and vascular net-
works [229].
The acellular muscle ECM has been also investigated in
muscletissue-engineeringﬁeld.Theacellularmusclescaﬀold
was derived from the extensor digitorum longus muscle,
and was injected with myoblasts. The constructs allowed
cell survival and proliferation and showed longitudinal con-
tractile force on electrical stimulation [230].
Eachtypeofscaﬀoldshowsspeciﬁcproprietiesandpecu-
liar advantages. The ﬁnal goal of scaﬀold fabrication con-
sists of promoting the proliferation of muscle stem cells,
their diﬀerentiation, and parallel alignment to obtain a new
skeletal muscle-like tissue [40, 84, 231–235]. The application
of scaﬀold for regeneration of muscle tissue could represents
an interesting approach particularly in the major trauma
with large loss of tissue. In the majority of muscle injuries,
the role of scaﬀold remains unclear and maybe not as im-
portant as in bone or cartilage regeneration. In fact, the
skeletal muscle is characterized by diﬀerent layer of connec-
tive tissue, such as endomysium, perimysium, and epimy-
sium,whichseemstobeabletodrivetheregenerationofnew
muscle-ﬁbers without the need of scaﬀold [12, 24, 87, 236–
245]. Furtherstudies arerequired to identify thebest scaﬀold
for skeletal muscle tissue engineering. However, the com-
binationofavailabletechniquescouldrepresenttherightway
to fabricate the ideal scaﬀold.
6. Conclusion
Skeletal muscle injuries are the most common injury in
sport, occurring with direct and indirect mechanisms. Their
eﬀective management is a challenging issue in orthopaedic
sport medicine because of the residual eﬀects, such as se-
vere long-term pain and physical disability. Skeletal muscle
injuriescausetimelossofactivityandincreasedriskofrecur-
rent injury. For these reasons, they constitute a health pro-
blem for athletes and an economic problem for clubs and
sponsors.
In most of the instances, current therapy consists of con-
servative management including RICE protocol and admin-
istration of NSAIDs or intramuscular corticosteroids. How-
ever, current management of muscle injuries does not often
provide an optimal restore of preinjury status because of the
ﬁbrosis which occurs during the repair process of injured
muscle. Experimental studies highlight the biological bases
ofmusclehealingaftercontusion,strain,orlacerationinjury.
Thisprovidestherationalebasisfornewbiologicaltherapies,
such as PRP and growth factors, cell-based therapy and tis-
sue engineering [62, 70, 84, 233, 237, 243, 245]. Biological
strategies may well be more favourable to healing. Although
PRP application is encouraged, reasons for concern persist
in its use for muscle injury management, and its mechanism
of action remains uncertain. Further research is required to
allow a standardized and safety use of this product in clinical
practice [73]. Cell-based strategies have been investigated
onlyinlimitedandinconsistentstudies.Theroleofstemcells
needs to be conﬁrmed. Further research is required to iden-
tify mechanisms involved in muscle regeneration and in sur-
vival, proliferation, and diﬀerentiation of stem cells. Skeletal
muscle tissue engineering represents a biological alter-
nativeforreplacementoflargetissuelossafterseveredamage,
based on combination of adult or embryonic stem cells,
factors or stimuli, and biomaterials. However, further studies
are required to identify the best biomaterial to fabricate the
idealscaﬀold,thebestcellsourceforscaﬀoldseeding,andthe
role of growth factors and other stimuli used to functionalize
the scaﬀold.
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